Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.

[1]  G. Pugliese,et al.  Emergence of Antibiotic-Resistant Pseudomonas aeruginosa , 1999, Infection Control & Hospital Epidemiology.

[2]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Y. Carmeli,et al.  Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents , 1999, Antimicrobial Agents and Chemotherapy.

[4]  Y. Carmeli,et al.  Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. , 1999, Archives of internal medicine.

[5]  R. Gaynes,et al.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1999, Critical care medicine.

[6]  R N Jones,et al.  Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. , 1999, Diagnostic microbiology and infectious disease.

[7]  R. Gaynes,et al.  Nosocomial Infections in Pediatric Intensive Care Units in the United States , 1999, Pediatrics.

[8]  R N Jones,et al.  Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. , 1998, Diagnostic microbiology and infectious disease.

[9]  Ronald N. Jones,et al.  Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) , 1998, Antimicrobial Agents and Chemotherapy.

[10]  Ronald N. Jones,et al.  Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States , 1998 .

[11]  J. Quinn,et al.  Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Kessler,et al.  Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period. , 1996, The American journal of medicine.

[13]  R. Gaynes,et al.  Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. , 1994, The Journal of infectious diseases.

[14]  R. Gaynes,et al.  Major trends in the microbial etiology of nosocomial infection. , 1991, The American journal of medicine.